For PPP2R1A a heterozygous somatic mutation (c.771G>T p.W257C) was identified in 1 out of 37 patients (2.7%) with primary ovarian endometrioid carcinoma.
This study indicates that the PPP2R1A mutation occurs at a lower frequency compared to other gynecological malignancies irrespective of the histological subtype
Our findings suggest that functional genetic variants in the proximal promoter of the PP2A-Aalpha gene and their haplotypes are critical in the regulation of transcriptional activation.
the frequent mutation of PPP2R1A in the serous type of uterine cancer a low frequency of mutation in endometrioid endometrial cancer and absence of mutation in uterine carcinosarcoma.
identified somatic missense mutations in 40.8% of high-grade serous endometrial tumours and 5% of endometrial endometrioid carcinomas; mutations identified in ovarian tumours at lower frequencies;no mutations found in high- or low-grade serous carcinoma
genes mutated in ovarian clear cell carcinoma(OCCC);data suggest PPP2R1A functions as an oncogene and ARID1A as tumor-suppressor gene; in 42 OCCCs 7% had mutations in PPP2R1A and 57% in ARID1A; suggests aberrant chromatin remodeling contributes to OCCC
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.